Stay updated with breaking news from Image Analysis Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
#industry #news #UK #2024 #insights #zenopa #recruitment #Healthcare #communications #Sheedy #Kubassova #Chief #Executive #Image #Analysis #Group #nominated #biopharmaceutical #assessment #service #provider
Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.
Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.
Findings from cross-sectional and predictive analyses of patients with UC treated with upadacitinib revealed HEMR and HEMI are associated with positive long-term clinical outcomes.
The Business Research Company’s Medical Image Analysis Software Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032